39740-30-2
Chemical Structure
Etilevodopa hydrochloride
Synonym(s): L-DOPA ethyl ester hydrochloride; Levodopa ethyl ester hydrochloride
- CAS No.: 39740-30-2
- Formula:C11H16ClNO4
- Molecular Weight:261.70
IUPAC Name: ethyl (S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate hydrochloride
InChIKey: CVQFXVIIFKVRCK-QRPNPIFTSA-N
SMILES: N[C@@H](CC1=CC=C(O)C(O)=C1)C(OCC)=O.[H]Cl
Biological Activity: Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Etilevodopa hydrochloride | 99.40% | Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Etilevodopa hydrochloride (Standard) | ≥98% | Etilevodopa (hydrochloride) (Standard) is the analytical standard of Etilevodopa (hydrochloride). This product is intended for research and analytical applications. Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Djaldetti R, et al. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol. 2003 Nov-Dec;26(6):322-6. [Content Brief]
- [2]. Blindauer K, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb;63(2):210-6. [Content Brief]
- [3]. Haddad F, et al. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease. Molecules. 2017 Dec 25;23(1). pii: E40. [Content Brief]
